However, recent phase II trials (NCT02684058 and NCT04775485) found that dabrafenib plus trametinib could be an effective therapy as first-line treatment for pediatric patients with low-grade glioma with BRAF V600 mutations (18), and type II RAF inhibitor tovorafenib could be an effective therapy for BRAF-altered, relapsed/refractory pediatric low-grade glioma (19). The gene discussed is BRAF; the disease is central nervous system cancer.